RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Background: Severe acute respiratory syndrome coronavirus 2 (SARS−CoV−2) infections and the resulting disease, coronavirus disease 2019 (COVID−19), have spread to millions of people globally. Multiple vaccine candidates are under development, but no vaccine is currently available. Methods: Healthy a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:medRxiv
Auteurs principaux: Walsh, Edward E., Frenck, Robert, Falsey, Ann R., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Neuzil, Kathleen, Mulligan, Mark J, Bailey, Ruth, Swanson, Kena A, Li, Ping, Koury, Kenneth, Kalina, Warren, Cooper, David, Fontes-Garfias, Camila, Shi, Pei-Yong, Türeci, Özlem, Thompkins, Kristin R, Lyke, Kirsten E., Raabe, Vanessa, Dormitzer, Philip R, Jansen, Kathrin U, Sahin, Uğur, Gruber, William C.
Format: Artigo
Langue:Inglês
Publié: Cold Spring Harbor Laboratory 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444302/
https://ncbi.nlm.nih.gov/pubmed/32839784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.08.17.20176651
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires